Bexxar tositumomab: Phase II; BLA under review

CLTR and partner SmithKline Beecham (LSE:SB;SBH, Philadelphia, Penn.) said that in a Phase II trial of Bexxar in patients with NHL who had failed to respond to or progressed following treatment with ...